Together, the two organizations have created a unique alliance that blends the academic prowess of LJI with the drug development and commercialization expertise of Kyowa Kirin.
"Our ultimate goal is to develop vaccines against these very difficult viruses. Understanding how these viruses manipulate the immune response can help guide the development of the best vaccine approach."
Scientists at La Jolla Institute for Immunology (LJI) are advancing new cancer research programs, thanks to more than $1.7 million in funding from the San Diego philanthropic organization Curebound.
This research comes as dengue-carrying mosquitos expand their territory into new regions, including Southern California.
"This antibody offers the best protection in primates, at the lowest dose yet seen for any single antibody."
"If we can target these molecules in human patients, they might be able to develop long-lasting tolerance to allergens."
Pathogen-fighting immune cells called tissue-resident memory CD8 T cells go through a surprising transformation鈥攁nd relocation鈥攁s they fight infections in the small intestine.
"This research holds enormous potential to transform the field of cancer immunotherapy..."
La Jolla Institute for Immunology (LJI) and Link Campus University of Rome, Italy, and have signed a collaborative agreement as part of a strategic program aimed at promoting scientific research and innovation between the United States and Italy.
LA JOLLA, CA鈥擫a Jolla Institute for Immunology (LJI) Professor Sujan Shresta, Ph.D., is on hand to share her expertise on dengue fever and dengue vaccine development. She is available to comment on urgent dengue virus research amidst the news of San Diego鈥檚 first locally acquired dengue virus case. LJI Professor Sujan Shresta, Ph.
The new study, led by researchers in the Saphire Lab at LJI, reveals the inner workings of the Ebola virus nucleocapsid. LA JOLLA, CA鈥擜t this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.
The LJI team uncovered important similarities between H5N1 and these common viruses, which allowed them to predict that many people already have "cross-reactive" T cells that are ready to target H5N1鈥攕hould it ever mutate to cause widespread disease in humans.
La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Scientists at La Jolla Institute for Immunology (LJI) are investigating how the mutated clade 1 mpox virus may affect children and older patients鈥攁nd how new vaccines can help the body fight back.
"As an infectious diseases clinician, I've always been focused on research into pathogen-host interactions. We need to know why some people get sicker than others."
The researchers hope to one day target this T cell population via drug therapy. "These cells may be a very important target for treating ulcerative colitis and perhaps other autoimmune diseases..."
LA JOLLA, CA鈥擲cientists at La Jolla Institute for Immunology (LJI) have developed a new computational method for linking molecular marks on our DNA to gene activity. Their work may help researchers connect genes to the molecular 鈥渟witches鈥� that turn them on or off. This research, published in Genome Biology, is an important step toward harnessing machine learning approaches to better understand links between gene expression and disease development.
Repeated vaccination and infection leads T cells and B cells to build an "immunity wall"
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
